Gender difference in the pathophysiology and treatment of glaucoma

Current Eye Research

Volumn 40, Issue 2, 2015, Pages 191-200

  Tehrani, Shandiz ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Gender; Glaucoma; Hormone therapy; Intraocular pressure; Pregnancy

Indexed keywords

HORMONE;

ANATOMIC LANDMARK; CLOSED ANGLE GLAUCOMA; ENDOCRINOLOGY; EPIDEMIOLOGY; GLAUCOMA; HUMAN; NONHUMAN; OPEN ANGLE GLAUCOMA; PATHOPHYSIOLOGY; PATIENT SAFETY; PREGNANCY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SEX DIFFERENCE; TREATMENT OUTCOME; FEMALE; INTRAOCULAR PRESSURE; MALE; PHYSIOLOGY;

FEMALE; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE; MALE; PREGNANCY; RISK FACTORS; SEX FACTORS;

EID: 84921667372     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.3109/02713683.2014.968935     Document Type: Review

References (123)

1. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 2006;90:262-267.
2. Burgoyne CF. A biomechanical paradigm for axonal insult within the optic nerve head in aging and glaucoma. Exp Eye Res 2010;93:120-132.
3. Dai C, Khaw PT, Yin ZQ, Li D, Raisman G, Li Y. Structural basis of glaucoma: The fortified astrocytes of the optic nerve head are the target of raised intraocular pressure. Glia 2012;60:13-28.
4. Kwon YH, Fingert JH, Kuehn MH, Alward WL. Primary open-angle glaucoma. N Engl J Med 2009;360: 1113-1124.
5. Quigley HA, Addicks EM. Regional differences in the structure of the lamina cribrosa and their relation to glaucomatous optic nerve damage. Arch Ophthalmol 1981; 99:137-143.
6. Alward WL, et al. (Collaborative Normal-Tension Glaucoma Study Group). The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol 1998;126:498-505.
7. Alward WL, et al. (Collaborative Normal-Tension Glaucoma Study Group). Comparison of glaucomatous progression between untreated patients with normaltension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol 1998;126:487-497.
8. Gordon MO, Kass MA. The Ocular Hypertension Treatment Study: Design and baseline description of the participants. Arch Ophthalmol 1999;117:573-583.
9. Gordon MO, Beiser JA, Brandt JD, Heuer DK, Higginbotham EJ, Johnson CA, et al. The Ocular Hypertension Treatment Study: Baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120:714-720; discussion 829-30.
10. Sommer A. Glaucoma risk factors observed in the Baltimore Eye Survey. Curr Opin Ophthalmol 1996;7: 93-98.
11. Hovding G, Aasved H. Prognostic factors in the development of manifest open angle glaucoma. A long-term follow-up study of hypertensive and normotensive eyes. Acta Ophthalmol (Copenh) 1986;64:601-608.
12. Wilson MR, Hertzmark E, Walker AM, Childs-Shaw K, Epstein DL. A case-control study of risk factors in open angle glaucoma. Arch Ophthalmol 1987;105:1066-1071.
13. Brandt JD, Beiser JA, Kass MA, Gordon MO. Central corneal thickness in the Ocular Hypertension Treatment Study (OHTS). Ophthalmology 2001;108:1779-1788.
14. Burgoyne C. Myopic eyes and glaucoma. J Glaucoma 2004;13:85-86.
15. Phelps CD. Effect of myopia on prognosis in treated primary open-angle glaucoma. Am J Ophthalmol 1982;93: 622-628.
16. Hayreh SS, Zimmerman MB, Podhajsky P, Alward WL. Nocturnal arterial hypotension and its role in optic nerve head and ocular ischemic disorders. Am J Ophthalmol 1994;117:603-624.
17. Vajaranant TS, Pasquale LR. Estrogen deficiency accelerates aging of the optic nerve. Menopause 2012;19:942-947.
18. Vajaranant TS, Grossardt BR, Maki PM, Pasquale LR, Sit AJ, Shuster LT, et al. Risk of glaucoma after early bilateral oophorectomy. Menopause 2014;21:391-398.
19. Lee AJ, Mitchell P, Rochtchina E, Healey PR, Blue Mountains Eye S. Female reproductive factors and open angle glaucoma: The Blue Mountains Eye Study. Br J Ophthalmol 2003;87:1324-1328.
20. Pasquale LR, Kang JH. Female reproductive factors and primary open-angle glaucoma in the Nurses' Health Study. Eye (Lond) 2011;25:633-641.
21. Hulsman CA, Westendorp IC, Ramrattan RS, Wolfs RC, Witteman JC, Vingerling JR, et al. Is open-angle glaucoma associated with early menopause? The Rotterdam Study. Am J Epidemiol 2001;154:138-144.
22. Newman-Casey PA, Talwar N, Nan B, Musch DC, Pasquale LR, Stein JD. The potential association between postmenopausal hormone use and primary open-angle glaucoma. JAMA Ophthalmol 2014;132:298-303.
23. Razeghinejad MR, Tania Tai TY, Fudemberg SJ, Katz LJ. Pregnancy and glaucoma. Surv Ophthalmol 2011;56: 324-335.
24. Ebeigbe JA, Ebeigbe PN, Ighoroje A. Ocular changes in pregnant Nigerian women. Niger J Clin Pract 2012;15: 298-301.
25. Efe YK, Ugurbas SC, Alpay A, Ugurbas SH. The course of corneal and intraocular pressure changes during pregnancy. Can J Ophthalmol 2012;47:150-154.
26. Akar Y, Yucel I, Akar ME, Zorlu G, Ari ES. Effect of pregnancy on intraobserver and intertechnique agreement in intraocular pressure measurements. Ophthalmologica 2005;219:36-42.
27. De Santis M, Lucchese A, Carducci B, Cavaliere AF, De Santis L, Merola A, et al. Latanoprost exposure in pregnancy. Am J Ophthalmol 2004;138:305-306.
28. Mendez-Hernandez C, Garcia-Feijoo J, Saenz-Frances F, Santos-Bueso E, Martinez-de-la-Casa JM, Megias AV, et al. Topical intraocular pressure therapy effects on pregnancy. Clin Ophthalmol 2012;6:1629-1632.
29. Tielsch JM, Sommer A, Katz J, Royall RM, Quigley HA, Javitt J. Racial variations in the prevalence of primary open-angle glaucoma: The Baltimore Eye Survey. JAMA 1991;266:369-374.
30. Klein BE, Klein R, Sponsel WE, Franke T, Cantor LB, Martone J, et al. Prevalence of glaucoma. The Beaver Dam Eye Study. Ophthalmology 1992;99:1499-1504.
31. Kahn HA, Leibowitz HM, Ganley JP, Kini MM, Colton T, Nickerson RS, et al. The Framingham Eye Study. II. Association of ophthalmic pathology with single variables previously measured in the Framingham Heart Study. Am J Epidemiol 1977;106:33-41.
32. Jiang X, Varma R, Wu S, Torres M, Azen SP, Francis BA, et al. Baseline risk factors that predict the development of open-angle glaucoma in a population: The Los Angeles Latino Eye Study. Ophthalmology 2012;119:2245-2253.
33. Rodriguez J, Sanchez R, Munoz B, West SK, Broman A, Snyder RW, et al. Causes of blindness and visual impairment in a population-based sample of U.S. Hispanics. Ophthalmology 2002;109:737-743.
34. Mitchell P, Smith W, Attebo K, Healey PR. Prevalence of open-angle glaucoma in Australia. The Blue Mountains Eye Study. Ophthalmology 1996;103:1661-1669.
35. Leske MC, Connell AM, Schachat AP, Hyman L. The Barbados Eye Study: Prevalence of open angle glaucoma. Arch Ophthalmol 1994;112:821-829.
36. Dielemans I, Vingerling JR, Wolfs RC, Hofman A, Grobbee DE, de Jong PT. The prevalence of primary open-angle glaucoma in a population-based study in The Netherlands. The Rotterdam Study. Ophthalmology 1994; 101:1851-1855.
37. Morrison J, Pollack IP, editors. Glaucoma: Science and practice. New York: Thieme Publishers; 2003.
38. Alsbirk PH. Anatomical risk factors in primary angleclosure glaucoma. A ten year follow up survey based on limbal and axial anterior chamber depths in a high risk population. Int Ophthalmol 1992;16:265-272.
39. Wojciechowski R, Congdon N, Anninger W, Teo Broman A. Age, gender, biometry, refractive error, and the anterior chamber angle among Alaskan Eskimos. Ophthalmology 2003;110:365-375.
40. Van Rens GH, Arkell SM, Charlton W, Doesburg W. Primary angle-closure glaucoma among Alaskan Eskimos. Doc Ophthalmol 1988;70:265-276.
41. Seah SK, Foster PJ, Chew PT, Jap A, Oen F, Fam HB, et al. Incidence of acute primary angle-closure glaucoma in Singapore. An island-wide survey. Arch Ophthalmol 1997;115:1436-1440.
42. Casson RJ, Marshall D, Newland HS, McGovern S, Muecke J, Tan EW, et al. Risk factors for early angleclosure disease in a Burmese population: The Meiktila Eye Study. Eye (Lond) 2009;23:933-939.
43. Wang YX, Xu L, Yang H, Jonas JB. Prevalence of glaucoma in North China: The Beijing Eye Study. Am J Ophthalmol 2010;150:917-924.
44. Xu L, You QS, Wang YX, Jonas JB. Associations between gender, ocular parameters and diseases: The Beijing Eye study. Ophthalmic Res 2011;45:197-203.
45. Xu L, Cao WF, Wang YX, Chen CX, Jonas JB. Anterior chamber depth and chamber angle and their associations with ocular and general parameters: The Beijing Eye Study. Am J Ophthalmol 2008;145:929-936.
46. Liang Y, Friedman DS, Zhou Q, Yang XH, Sun LP, Guo L, et al. Prevalence and characteristics of primary angleclosure diseases in a rural adult Chinese population: The Handan Eye Study. Invest Ophthalmol Vis Sci 2011;52: 8672-8679.
47. Song W, Shan L, Cheng F, Fan P, Zhang L, Qu W, et al. Prevalence of glaucoma in a rural northern china adult population: A population-based survey in Kailu county, inner Mongolia. Ophthalmology 2011;118:1982-1988.
48. Senthil S, Garudadri C, Khanna RC, Sannapaneni K. Angle closure in the Andhra Pradesh Eye Disease Study. Ophthalmology 2010;117:1729-1735.
49. Erie JC, Hodge DO, Gray DT. The incidence of primary angle-closure glaucoma in Olmsted County, Minnesota. Arch Ophthalmol 1997;115:177-181.
50. Ng WS, Ang GS, Azuara-Blanco A. Primary angle closure glaucoma: A descriptive study in Scottish Caucasians. Clin Experiment Ophthalmol 2008;36:847-851.
51. Sng CC, Foo LL, Cheng CY, Allen Jr JC, He M, Krishnaswamy G, et al. Determinants of anterior chamber depth: The Singapore Chinese Eye Study. Ophthalmology 2012;119:1143-1150.
52. Wang B, Sakata LM, Friedman DS, Chan YH, He M, Lavanya R, et al. Quantitative iris parameters and association with narrow angles. Ophthalmology 2010;117: 11-17.
53. Levene RZ. Low tension glaucoma: A critical review and new material. Surv Ophthalmol 1980;24:621-664.
54. Shields MB. Normal-tension glaucoma: Is it different from primary open-angle glaucoma? Curr Opin Ophthalmol 2008;19:85-88.
55. Conway RM, Schlotzer-Schrehardt U, Kuchle M, Naumann GO. Pseudoexfoliation syndrome: Pathological manifestations of relevance to intraocular surgery. Clin Experiment Ophthalmol 2004;32:199-210.
56. Niyadurupola N, Broadway DC. Pigment dispersion syndrome and pigmentary glaucoma-A major review. Clin Experiment Ophthalmol 2008;36:868-882.
57. Dielemans I, de Jong PT, Stolk R, Vingerling JR, Grobbee DE, Hofman A. Primary open-angle glaucoma, intraocular pressure, and diabetes mellitus in the general elderly population: The Rotterdam Study. Ophthalmology 1996; 103:1271-1275.
58. Drance S, Anderson DR, Schulzer M, Collaborative Normal-Tension Glaucoma Study G. Risk factors for progression of visual field abnormalities in normaltension glaucoma. Am J Ophthalmol 2001;131:699-708.
59. Alward WLM. Glaucoma. In: Krachmer JH, editor. The requisites in ophthalmology. St. Louis, MO: Mosby; 2000:136-138.
60. Ringvold A, Blika S, Elsas T, Guldahl J, Brevik T, Hesstvedt P, et al. The middle-Norway eye-screening study: II. Prevalence of simple and capsular glaucoma. Acta Ophthalmol (Copenh) 1991;69:273-280.
61. Cashwell Jr LF, Shields MB. Exfoliation syndrome in the southeastern United States. I. Prevalence in openangle glaucoma and non-glaucoma populations. Acta Ophthalmol Suppl 1988;184:99-102.
62. Fan BJ, Pasquale LR, Rhee D, Li T, Haines JL, Wiggs JL. LOXL1 promoter haplotypes are associated with exfoliation syndrome in a U.S. Caucasian population. Invest Ophthalmol Vis Sci 2011;52:2372-2378.
63. Nouri-Mahdavi K, Nosrat N, Sahebghalam R, Jahanmard M. Pseudoexfoliation syndrome in central Iran: A population-based survey. Acta Ophthalmol Scand 1999;77:581-584.
64. McCarty CA, Taylor HR. Pseudoexfoliation syndrome in Australian adults. Am J Ophthalmol 2000;129: 629-633.
65. Rotchford AP, Kirwan JF, Johnson GJ, Roux P. Exfoliation syndrome in black South Africans. Arch Ophthalmol 2003;121:863-870.
66. Young AL, Tang WW, Lam DS. The prevalence of pseudoexfoliation syndrome in Chinese people. Br J Ophthalmol 2004;88:193-195.
67. Thomas R, Nirmalan PK, Krishnaiah S. Pseudoexfoliation in southern India: The Andhra Pradesh Eye Disease Study. Invest Ophthalmol Vis Sci 2005;46:1170-1176.
68. Astrom S, Stenlund H, Linden C. Incidence and prevalence of pseudoexfoliations and open-angle glaucoma in northern Sweden: II. Results after 21 years of follow-up. Acta Ophthalmol Scand 2007;85:832-837.
69. Al-Bdour MD, Al-Till MI, Idrees GM, Abu Samra KM. Pseudoexfoliation syndrome at Jordan University Hospital. Acta ophthalmologica 2008;86:755-757.
70. Ozaki M, Lee KY, Vithana EN, Yong VH, Thalamuthu A, Mizoguchi T, et al. Association of LOXL1 gene polymorphisms with pseudoexfoliation in the Japanese. Invest Ophthalmol Vis Sci 2008;49:3976-3980.
71. Rudkin AK, Edussuriya K, Sennanayake S, Senaratne T, Selva D, Sullivan TR, et al. Prevalence of exfoliation syndrome in central Sri Lanka: The Kandy Eye Study. Br J Ophthalmol 2008;92:1595-1598.
72. Viso E, Rodriguez-Ares MT, Gude F. Prevalence of pseudoexfoliation syndrome among adult Spanish in the Salnes eye Study. Ophthalmic Epidemiol 2010;17:118-124.
73. Kaimbo Wa Kaimbo D. Pseudoexfoliation syndrome in Congolese patients. J Fr Ophtalmol 2012;35:40-45.
74. Olawoye OO, Ashaye AO, Teng CC, Liebmann JM, Ritch R, Ajayi BG. Exfoliation syndrome in Nigeria. Middle East Afr J Ophthalmol 2012;19:402-405.
75. Arnarsson AM. Epidemiology of exfoliation syndrome in the Reykjavik Eye Study. Acta Ophthalmol 2009;87:1-17 (Thesis 3).
76. Kang JH, Loomis S, Wiggs JL, Stein JD, Pasquale LR. Demographic and geographic features of exfoliation glaucoma in 2 United States-based prospective cohorts. Ophthalmology 2012;119:27-35.
77. Miyazaki M, Kubota T, Kubo M, Kiyohara Y, Iida M, Nose Y, et al. The prevalence of pseudoexfoliation syndrome in a Japanese population: The Hisayama study. J Glaucoma 2005;14:482-484.
78. Richter CU, Richardson TM, Grant WM. Pigmentary dispersion syndrome and pigmentary glaucoma. A prospective study of the natural history. Arch Ophthalmol 1986;104:211-215.
79. Migliazzo CV, Shaffer RN, Nykin R, Magee S. Long-term analysis of pigmentary dispersion syndrome and pigmentary glaucoma. Ophthalmology 1986;93:1528-1536.
80. Scheie HG, Cameron JD. Pigment dispersion syndrome: A clinical study. Br J Ophthalmol 1981;65:264-269.
81. Farrar SM, Shields MB, Miller KN, Stoup CM. Risk factors for the development and severity of glaucoma in the pigment dispersion syndrome. Am J Ophthalmol 1989; 108:223-229.
82. Gillies WE, Brooks AM. Clinical features at presentation of anterior segment pigment dispersion syndrome. Clin Experiment Ophthalmol 2001;29:125-127.
83. Orgul S, Hendrickson P, Flammer J. Anterior chamber depth and pigment dispersion syndrome. Am J Ophthalmol 1994;117:575-577.
84. Paterson GD, Miller SJ. Hormonal influence in simple glaucoma: A preliminary report. Br J Ophthalmol 1963;47: 129-137.
85. Yucel I, Akar ME, Dora B, Akar Y, Taskin O, Ozer HO. Effect of the menstrual cycle on standard achromatic and blue-on-yellow visual field analysis of women with migraine. Can J Ophthalmol 2005;40:51-57.
86. Pasquale LR, Rosner BA, Hankinson SE, Kang JH. Attributes of female reproductive aging and their relation to primary open-angle glaucoma: A prospective study. J Glaucoma 2007;16:598-605.
87. Altintas O, Caglar Y, Yuksel N, Demirci A, Karabas L. The effects of menopause and hormone replacement therapy on quality and quantity of tear, intraocular pressure and ocular blood flow. Ophthalmologica 2004; 218:120-129.
88. Zhou X, Li F, Ge J, Sarkisian Jr SR, Tomita H, Zaharia A, et al. Retinal ganglion cell protection by 17-beta-estradiol in a mouse model of inherited glaucoma. Dev Neurobiol 2007;67:603-616.
89. Prokai-Tatrai K, Xin H, Nguyen V, Szarka S, Blazics B, Prokai L, et al. 17Beta-estradiol eye drops protect the retinal ganglion cell layer and preserve visual function in an in vivo model of glaucoma. Mol Pharm 2013;10: 3253-3261.
90. Zhang QG, Wang R, Tang H, Dong Y, Chan A, Sareddy GR, et al. Brain-derived estrogen exerts anti-inflammatory and neuroprotective actions in the rat hippocampus. Mol Cell Endocr 2014;389:84-91.
91. Wang C, Jie C, Dai X. Possible roles of astrocytes in estrogen neuroprotection during cerebral ischemia. Rev Neurosci 2014;25:255-268.
92. Dhandapani KM, Brann DW. Role of astrocytes in estrogen-mediated neuroprotection. Exp Gerontol 2007; 42:70-75.
93. Ding D, Starke RM, Dumont AS, Owens GK, Hasan DM, Chalouhi N, et al. Therapeutic implications of estrogen for cerebral vasospasm and delayed cerebral ischemia induced by aneurysmal subarachnoid hemorrhage. BioMed Res Int 2014;2014:1-9.
94. Pietranera L, Brocca ME, Roig P, Lima A, Garcia-Segura LM, De Nicola AF. 17alpha-Oestradiol-induced neuroprotection in the brain of spontaneously hypertensive rats. J Neuroendocrino 2014;26:310-320.
95. Pietranera L, Brocca ME, Roig P, Lima A, Garcia-Segura LM, De Nicola AF. Estrogens are neuroprotective factors for hypertensive encephalopathy. J Steroid Biochem Mol Biol 2014; [Epub ahead of print]; http://dx.doi.org/10.1016/j.jsbmb.2014.04.001.
96. Nakaso K, Tajima N, Horikoshi Y, Nakasone M, Hanaki T, Kamizaki K, et al. The estrogen receptor beta-PI3K/Akt pathway mediates the cytoprotective effects of tocotrienol in a cellular Parkinson's disease model. Biochim Biophys Acta 2014;1842:1303-1312.
97. Cue L, Diaz F, Briegel KJ, Patel HH, Raval AP. Periodic estrogen receptor-beta activation: A novel approach to prevent ischemic brain damage. Neurochem Res 2014; [Epub ahead of print]; http://dx.doi.org/10.1016/j.jsbmb.2014.04.001.
98. Pabon M, Tamboli C, Tamboli S, Acosta S, De La Pena I, Sanberg PR, et al. Estrogen replacement therapy for stroke. Cell Med 2014;6:111-122.
99. Zalewski A, Cecchini EL, Deroo BJ. Expression of extracellular matrix components is disrupted in the immature and adult estrogen receptor beta-null mouse ovary. PLoS One 2012;7:e29937.
100. Quigley HA, Flower RW, Addicks EM, McLeod DS. The mechanism of optic nerve damage in experimental acute intraocular pressure elevation. Invest Ophthalmol Vis Sci 1980;19:505-517.
101. Burgoyne CF, Quigley HA, Thompson HW, Vitale S, Varma R. Early changes in optic disc compliance and surface position in experimental glaucoma. Ophthalmology 1995;102:1800-1809.
102. Kang JH, Wiggs JL, Haines J, Abdrabou W, Pasquale LR. Reproductive factors and NOS3 variant interactions in primary open-angle glaucoma. Mol Vis 2011;17: 2544-2551.
103. Pasquale LR, Loomis SJ, Weinreb RN, Kang JH, Yaspan BL, Bailey JC, et al. Estrogen pathway polymorphisms in relation to primary open angle glaucoma: An analysis accounting for gender from the United States. Mol Vis 2013;19:1471-1481.
104. Florian M, Lu Y, Angle M, Magder S. Estrogen induced changes in Akt-dependent activation of endothelial nitric oxide synthase and vasodilation. Steroids 2004;69: 637-645.
105. Kreatsoulas C, Anand SS. Menopausal hormone therapy for the primary prevention of chronic conditions. U.S. Preventive Services Task Force recommendation statement. Pol Arch Med Wewn 2013;123:112-117.
106. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002;288: 321-333.
107. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998; 280:605-613.
108. Posthumus RG. [The use and the possibilities of progesterone in the treatment of glaucoma]. Ophthalmologica 1952;124:17-25.
109. Moyer VA, Force USPST. Menopausal hormone therapy for the primary prevention of chronic conditions: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2013;158:47-54.
110. Wang YE. Association between oral contraceptive use and glaucoma in the United States. American Academy of Ophthalmology Annual Meeting; 2013; New Orleans.
111. Kang JH, Lin S, Vajaranant TS. Glaucoma in women: The estrogen connection. EyeNet (AAO) 2014;4:29-31.
112. Barbazetto IA, Pizzarello LD. Ocular changes during pregnancy. Compr Ophthalmol Update 2007;8: 155-167.
113. Omoti AE,Waziri-Erameh JM, Okeigbemen VW. A review of the changes in the ophthalmic and visual system in pregnancy. Afr J Reprod Health 2008;12:185-196.
114. Phillips CI, Gore SM. Ocular hypotensive effect of late pregnancy with and without high blood pressure. Br J Ophthalmol 1985;69:117-119.
115. Green K, Phillips CI, Cheeks L, Slagle T. Aqueous humor flow rate and intraocular pressure during and after pregnancy. Ophthalmic Res 1988;20:353-357.
116. Qureshi IA. Intraocular pressure: Association with menstrual cycle, pregnancy and menopause in apparently healthy women. Chin J Physiol 1995;38:229-234.
117. Qureshi IA. Measurements of intraocular pressure throughout the pregnancy in Pakistani women. Chin Med Sci J 1997;12:53-56.
118. Qureshi IA, Xi XR, Wu XD, Pasha N, Huang YB. Effect of third trimester of pregnancy on diurnal variation of ocular pressure. Chin Med Sci J 1997;12:240-243.
119. Ebeigbe JA, Ebeigbe PN, Ighoroje AD. Intraocular pressure in pregnant and non-pregnant Nigerian women. Afr J Reprod Health 2011;15:20-23.
120. Qureshi IA, Xi XR, Yaqob T. The ocular hypotensive effect of late pregnancy is higher in multigravidae than in primigravidae. Graefes Arch Clin Exp Ophthalmol 2000; 238:64-67.
121. Wilke K. Episcleral venous pressure and pregnancy [proceedings]. Acta Ophthalmol Suppl 1975;125:40-41.
122. Qureshi IA. Intraocular pressure and pregnancy: A comparison between normal and ocular hypertensive subjects. Arch Med Res 1997;28:397-400.
123. Wertheim M, Broadway DC. Cyclodiode laser therapy to control intraocular pressure during pregnancy. Br J Ophthalmol 2002;86:1318-1319.